Ekso Bionics Holdings, Inc. to Post Q2 2024 Earnings of ($0.11) Per Share, HC Wainwright Forecasts (NASDAQ:EKSO)

Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) – Research analysts at HC Wainwright lifted their Q2 2024 earnings per share (EPS) estimates for Ekso Bionics in a report issued on Tuesday, April 30th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.11) for the quarter, up from their previous forecast of ($0.13). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Ekso Bionics’ current full-year earnings is ($0.43) per share. HC Wainwright also issued estimates for Ekso Bionics’ Q3 2024 earnings at ($0.09) EPS, Q4 2024 earnings at ($0.06) EPS, FY2024 earnings at ($0.43) EPS, Q1 2025 earnings at ($0.10) EPS, Q2 2025 earnings at ($0.05) EPS, Q3 2025 earnings at ($0.02) EPS, Q4 2025 earnings at ($0.01) EPS and FY2025 earnings at ($0.19) EPS.

Ekso Bionics (NASDAQ:EKSO) last released its quarterly earnings results on Monday, April 29th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.04). Ekso Bionics had a negative return on equity of 95.36% and a negative net margin of 79.48%. The firm had revenue of $3.76 million for the quarter, compared to analysts’ expectations of $4.99 million. During the same quarter in the prior year, the business earned ($0.33) earnings per share.

Separately, StockNews.com upgraded Ekso Bionics from a “sell” rating to a “hold” rating in a research note on Thursday, April 4th.

Ekso Bionics Trading Up 1.6 %

EKSO opened at $1.31 on Thursday. The firm has a market cap of $23.80 million, a P/E ratio of -1.35 and a beta of 1.63. The company has a quick ratio of 1.87, a current ratio of 2.81 and a debt-to-equity ratio of 0.33. Ekso Bionics has a 52 week low of $0.62 and a 52 week high of $3.13. The business has a fifty day simple moving average of $1.45 and a 200-day simple moving average of $1.62.

Institutional Trading of Ekso Bionics

A hedge fund recently bought a new stake in Ekso Bionics stock. Kent Lake Capital LLC purchased a new stake in Ekso Bionics Holdings, Inc. (NASDAQ:EKSO) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 141,158 shares of the company’s stock, valued at approximately $353,000. Kent Lake Capital LLC owned approximately 0.95% of Ekso Bionics at the end of the most recent reporting period. Institutional investors own 6.42% of the company’s stock.

Ekso Bionics Company Profile

Ekso Bionics Holdings, Inc designs, develops, sells, and rents exoskeleton products in the Americas, Germany, Poland, Europe, the Middle East, Africa, the Asia Pacific, and internationally. It operates in two segments, EksoHealth and EksoWorks. The EksoHealth segment designs, engineers, manufactures, and markets exoskeletons for applications in the medical markets.